argenx (NASDAQ:ARGX) Earns “Outperform” Rating from William Blair

argenx (NASDAQ:ARGX)‘s stock had its “outperform” rating reissued by stock analysts at William Blair in a report released on Friday,RTT News reports. William Blair also issued estimates for argenx’s FY2026 earnings at $26.61 EPS, FY2027 earnings at $28.62 EPS and FY2028 earnings at $40.92 EPS.

Several other equities analysts also recently weighed in on the company. JMP Securities boosted their target price on argenx from $606.00 to $696.00 and gave the company a “market outperform” rating in a research report on Tuesday, January 14th. HC Wainwright boosted their target price on argenx from $717.00 to $720.00 and gave the company a “buy” rating in a research report on Friday. Wedbush reissued an “outperform” rating and set a $655.00 target price on shares of argenx in a research report on Tuesday, December 3rd. Robert W. Baird downgraded argenx from an “outperform” rating to a “neutral” rating and boosted their target price for the company from $515.00 to $650.00 in a research report on Friday, November 1st. Finally, Wolfe Research upgraded argenx from a “peer perform” rating to an “outperform” rating and set a $697.00 price objective for the company in a report on Tuesday, November 12th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, eighteen have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, argenx presently has a consensus rating of “Moderate Buy” and a consensus target price of $661.17.

argenx Price Performance

NASDAQ:ARGX opened at $624.67 on Friday. argenx has a 1 year low of $349.86 and a 1 year high of $678.21. The stock’s 50 day simple moving average is $642.62 and its two-hundred day simple moving average is $590.74. The company has a market cap of $37.96 billion, a price-to-earnings ratio of -709.85 and a beta of 0.58.

argenx (NASDAQ:ARGX) last released its quarterly earnings data on Thursday, February 27th. The company reported $1.58 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.98 by $0.60. argenx had a negative return on equity of 1.45% and a negative net margin of 2.11%. The business had revenue of $761.22 million for the quarter, compared to the consensus estimate of $678.52 million. As a group, analysts anticipate that argenx will post 3.13 EPS for the current year.

Institutional Investors Weigh In On argenx

Hedge funds have recently made changes to their positions in the stock. Stifel Financial Corp lifted its stake in shares of argenx by 15.3% during the 3rd quarter. Stifel Financial Corp now owns 8,832 shares of the company’s stock worth $4,788,000 after purchasing an additional 1,170 shares during the last quarter. FMR LLC lifted its stake in shares of argenx by 35.9% during the 3rd quarter. FMR LLC now owns 4,793,472 shares of the company’s stock worth $2,598,445,000 after purchasing an additional 1,265,486 shares during the last quarter. Simplify Asset Management Inc. lifted its stake in shares of argenx by 64.0% during the 3rd quarter. Simplify Asset Management Inc. now owns 2,419 shares of the company’s stock worth $1,311,000 after purchasing an additional 944 shares during the last quarter. Stephens Inc. AR purchased a new stake in shares of argenx during the 4th quarter worth $310,000. Finally, Ritholtz Wealth Management lifted its stake in shares of argenx by 85.5% during the 4th quarter. Ritholtz Wealth Management now owns 898 shares of the company’s stock worth $552,000 after purchasing an additional 414 shares during the last quarter. 60.32% of the stock is currently owned by hedge funds and other institutional investors.

About argenx

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.